ReviewInternational journal of nanomedicine2025
Recent Advances in Nanoparticle-Based Antiretroviral Drug Delivery Systems for HIV Treatment and Prevention: A Comprehensive Review.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exploring the impact of nutrition and autophagy on infectious diseases to inform the development of homeostatic-nanomedicines for HIV-TB coinfections.Discover nano · 2026Review
- Advances in Vaccines Against Infectious Diseases.Vaccines · 2026Article
- TARDBP as a regulator of HIV-1 assembly and infection: a review of targeting the viral capsid precursor Pr55Gag and limiting viral core entry.Cell communication and signaling : CCS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: AIDS disease, caused by HIV, is a highly prevalent disease disturbing global health and swaying economic progress and social fidelity in the world. Purpose: Eradication and cure of HIV infection has been a difficult assignment, and not many highly effective drugs and vaccines are available in the present scenario. Besides, the suboptimal adherence, toxicity, resistance to available drugs, and presence of several viral reservoirs make lifelong HIV infection treatment very challenging. Furthermore, a cure for HIV infection cannot be attained properly unless the latency issue is addressed and antiretroviral drug delivery to its specific cellular reservoir sites for an extended time is resolved. The advancement in nanotechnology could solve these issues with the formulation of advanced drugs in the nano-scale range. Currently, several nano-based architectures and formulations like nanoparticles (gold, silver, copper, and ruthenium) as nanocarriers, carbon nanotubes, liposomes, micelles, and polymer nanomaterials with superior solubility, sustained release, target specificity, long-duration delivery, and simplification of drug-dose reductions are developed which could act as effective HIV drugs/vaccine transporters in combination with available drugs and formulations. Several nano-based drug delivery approaches are suggested to target the CD4+ T cells, which are the primary target of HIV infection. While using nanoparticle-based drug delivery systems for HIV treatment, usually, three main strategies, such as the intracellular delivery of the anti-retroviral drugs by the polymeric nanoparticles, brain delivery of the anti-retroviral drugs by the polymeric nanoparticles, and use of the polymeric nanomaterials as an adjuvant for the HIV vaccines, are followed. Conclusion: Though nanotechnology offers many advantages over the conventional system of medications, it also gives rise to many side effects and challenges that need to be rectified for its better application. This review discusses the status and limits of conventional drug treatment and the recent advancements and updated strategies in nano-therapeutics for HIV treatment and cures, along with the possible mechanism of action of nano-mediated drugs, clinical translational challenges, and prospects of advanced nano-drug delivery schemes in HIV prevention and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.